Pharvaris (NASDAQ:PHVS) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• Pharvaris (NASDAQ:PHVS) received a "sell (D-)" rating from Weiss Ratings, highlighting a negative outlook for the company's stock.
• Analysts have varied opinions on Pharvaris, with HC Wainwright rating it as a "buy" with a target price of $60, while Bank of America upgraded it to "neutral" with a new target of $27.
• The company reported a loss of ($0.94) earnings per share recently, missing analyst expectations of ($0.87), indicating challenges in its financial performance.

Pharvaris (NASDAQ:PHVS - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

A number of other analysts have also weighed in on PHVS. HC Wainwright began coverage on shares of Pharvaris in a research report on Wednesday, October 15th. They issued a "buy" rating and a $60.00 price objective on the stock. Bank of America upgraded shares of Pharvaris from an "underperform" rating to a "neutral" rating and increased their price objective for the company from $16.00 to $27.00 in a research note on Thursday, October 9th. Zacks Research upgraded shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Finally, JMP Securities lowered their target price on shares of Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research note on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.17.

Pharvaris Trading Down 0.0%

Shares of NASDAQ PHVS opened at $22.99 on Friday. The firm's 50-day moving average price is $23.20 and its 200-day moving average price is $19.74. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -6.84 and a beta of -2.77. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07). On average, equities analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the business. Boothbay Fund Management LLC purchased a new position in shares of Pharvaris in the 2nd quarter valued at about $285,000. California State Teachers Retirement System increased its stake in shares of Pharvaris by 9.8% in the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company's stock valued at $247,000 after purchasing an additional 1,257 shares in the last quarter. TFG Asset Management GP Ltd increased its stake in shares of Pharvaris by 48.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock valued at $3,311,000 after purchasing an additional 61,105 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock valued at $860,000 after purchasing an additional 7,879 shares in the last quarter. Finally, HighVista Strategies LLC increased its stake in shares of Pharvaris by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company's stock valued at $418,000 after purchasing an additional 971 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.